Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) is up 58% at $27.60 [3] - Aditxt, Inc. (ADTX) has increased by 27% to $4.01 [3] - TMC the metals company Inc. (TMC) is up 15% at $6.75 [3] - CDT Equity Inc. (CDT) has risen by 13% to $2.34 [3] - Verrica Pharmaceuticals Inc. (VRCA) is up 12% at $7.56 [3] - Compass Diversified (CODI) has increased by 9% to $7.59 [3] - mF International Limited (MFI) is up 7% at $21.99 [3] - CEA Industries Inc. (BNC) has risen by 7% to $6.42 [3] - Odyssey Marine Exploration, Inc. (OMEX) is up 7% at $2.07 [3] - Vuzix Corporation (VUZI) has increased by 4% to $2.48 [3] Group 2: Premarket Losers - Solo Brands, Inc. (SBDS) is down 12% at $7.35 [4] - Surrozen, Inc. (SRZN) has decreased by 10% to $14.75 [4] - Protagenic Therapeutics, Inc. (PTIX) is down 10% at $2.00 [4] - Antelope Enterprise Holdings Limited (AEHL) has fallen by 8% to $3.18 [4] - Zynex, Inc. (ZYXI) is down 7% at $1.47 [4] - Reading International, Inc. (RDI) has decreased by 7% to $1.21 [4] - GCL Global Holdings Ltd (GCL) is down 6% at $1.24 [4] - Lunai Bioworks Inc. (LNAI) has fallen by 5% to $1.22 [4] - Solid Biosciences Inc. (SLDB) is down 4% at $5.10 [4] - Foxx Development Holdings Inc. (FOXX) has decreased by 4% to $4.30 [4]

Core Insights - Heartbeam Inc's shares increased significantly by 43.3% to $0.86 in pre-market trading following the announcement of its regulatory strategy after the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software [1][2] Company Developments - Heartbeam is exploring multiple regulatory options, including an appeal process or a 510(k) resubmission to demonstrate that its device is equivalent to legally marketed products [1] Market Movements - Other notable pre-market stock movements include: - SMX PLC surged 73.1% to $30.12 after a previous jump of 194% [6] - Zenta Group Co Ltd gained 26.7% to $3.18 [6] - Waton Financial Ltd rose 21.1% to $3.74 [6] - Verrica Pharmaceuticals Inc increased by 9.7% to $7.36 after announcing a $50 million private placement [6] - Conversely, several companies experienced declines, such as: - FBS Global Ltd fell 24.3% to $0.51 [6] - Tilray Brands Inc declined 15% to $0.88 following a reverse stock split announcement [6] - Solo Brands Inc dipped 14.4% to $7.19 after reporting disappointing third-quarter results [6]

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 14, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 59 Front Street Millbrook, NY 12545 Tel.: (646) 387-7129 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 General Purpose Acquisition Corp. (Exact ...

Core Viewpoint - Conduit Pharmaceuticals Inc. has received approval from Nasdaq to transfer its common stock listing to The Nasdaq Capital Market, effective May 23, 2025, following compliance with necessary requirements [1]. Company Overview - Conduit Pharmaceuticals is a clinical stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [2]. - The company utilizes a platform-driven approach powered by artificial intelligence (AI) and cybernetics, aiming for exits through third-party license deals after successful clinical trials [2]. - The leadership team includes experienced executives such as Dr. Andrew Regan and Dr. Freda Lewis-Hall, marking a shift from traditional pharma/biotech business models [2].

Leadership Changes - Conduit Pharmaceuticals announced key leadership changes to support its next phase of growth, with Dr. Andrew Regan appointed as the new CEO, succeeding Dr. David Tapolczay, who will remain as Head of Strategy & Licensing [1][2][4] - Dr. Regan has a successful entrepreneurial background, having sold Hobson Plc for £154 million and being a founding shareholder of Asos plc, which grew to a market capitalization exceeding £4.8 billion [3] Strategic Focus - The company aims to maximize shareholder value through licensing opportunities, creating new 20-year Composition-of-Matter patents, and utilizing AI and Cybernetics in collaboration with Sarborg to repurpose drugs [4] - Dr. Tapolczay highlighted the company's achievements, including its public listing on NASDAQ and a licensing deal with AstraZeneca, while expressing confidence in Dr. Regan's leadership [4] Company Overview - Conduit Pharmaceuticals is a multi-asset clinical stage life science company focused on an efficient model for compound development, acquiring and funding Phase 2-ready assets [5] - The company seeks to build an integrated platform-driven approach powered by AI and cybernetics, aiming for exits through third-party license deals following successful clinical trials [5]

Core Viewpoint - Conduit Pharmaceuticals has filed two innovative patents for tapinarof (VTAMA®), aiming to enhance its therapeutic profile and commercial viability as it approaches the expiration of exclusivity in 2027, positioning the company for lucrative licensing partnerships [1][2][3] Group 1: Patent and Product Development - The new patents include a dual active cocrystal formulation that combines tapinarof with a complementary drug substance, targeting both inflammatory skin conditions and associated symptoms like pain and itch [1][2] - This innovative approach differentiates Conduit's intellectual property from existing formulations, potentially offering partners a next-generation asset with significant commercial viability [2][3] - The company believes this new intellectual property could lead to formulations that improve patient tolerability, extend patent protection, and expand therapeutic applications [3][4] Group 2: Market Potential and Strategy - The global market for anti-inflammatory therapies is projected to exceed $233.6 billion by 2032, indicating substantial growth potential for tapinarof as its mechanism of action becomes increasingly relevant across various inflammatory conditions [3][4] - The anti-inflammatory therapeutics market is growing at nearly 9% annually, while dermatology treatments are expected to maintain a growth rate of 6-8% through 2030, presenting a unique opportunity for Conduit to maximize tapinarof's market potential [4][5] - The company is actively pursuing partnerships to leverage this breakthrough intellectual property while continuing to advance its broader pipeline [5]

Core Viewpoint - Conduit Pharmaceuticals Inc. has authorized a share repurchase program to buy back up to $1,000,000 of its common stock, believing the current market price does not reflect its underlying value [1][4]. Share Repurchase Program - The program allows Conduit to repurchase shares through open market transactions or other methods, adhering to SEC Rule 10b-18, with purchases executed by The Benchmark Company [2]. - There is no obligation for the company to acquire a specific amount of stock, and the program has no fixed expiration date, allowing for adjustments or termination at any time [3]. Company Overview - Conduit is a clinical-stage life science company focused on an efficient model for compound development, acquiring and funding Phase 2-ready assets [4]. - The company employs a platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party license deals after successful clinical trials [4]. - The leadership team includes experienced pharmaceutical executives, indicating a strong foundation for the company's innovative approach [4].

Core Insights - Conduit Pharmaceuticals has expanded its partnership with Sarborg to utilize advanced machine learning for analyzing clinical data from AstraZeneca-acquired assets, aiming to optimize development pathways and uncover new insights [1][2] Group 1: Partnership Details - The new agreement allows Sarborg to apply its proprietary machine learning algorithms to analyze Conduit's clinical and safety data, focusing on identifying missed insights and potential drug repurposing opportunities [2] - The collaboration includes a non-exclusive, non-transferable license for Conduit to access Sarborg's advanced algorithmic platform for six months, building on an existing Services Agreement [3] Group 2: Strategic Goals - The partnership aims to re-evaluate historical clinical trial data to identify specific patient subgroups that may have shown therapeutic benefits, which could refine Conduit's future clinical development strategy [2] - Dr. David Tapolczay, CEO of Conduit Pharmaceuticals, emphasized the commitment to leveraging data science to maximize the potential of their pipeline, particularly for key assets like AZD1656 [4] Group 3: Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on an efficient model for compound development, acquiring and funding Phase 2-ready assets while utilizing AI and cybernetics [4] - The company aims for exits through third-party license deals following successful clinical trials, representing a departure from traditional pharma/biotech business models [4]

Core Insights - Presidio Property Trust reported a net loss of approximately $27.9 million for the year ended December 31, 2024, compared to a net gain of approximately $8.0 million for 2023, reflecting a significant decline in profitability [4][29] - Total revenue increased by approximately $1.3 million or 7.3%, reaching approximately $18.9 million in 2024, driven by strong rent collections and new commercial leases [4][29] - The company successfully renewed 83% of expiring leases during the fourth quarter of 2024, indicating a positive leasing outlook for 2025 [2] Financial Performance - The company recorded general and administrative expenses of approximately $7.5 million for 2024, an increase of approximately $0.7 million or 10.8% compared to 2023 [4] - Funds from Operations (FFO) improved by approximately $2.8 million, moving from $(6.2 million) in 2023 to approximately $(3.4 million) in 2024 [6] - Core FFO also showed improvement, increasing by about $3.2 million from approximately $(5.2 million) in 2023 to approximately $(2.0 million) in 2024 [7] Asset Management - The company acquired 19 model home properties for $9.7 million in 2024, financed through cash payments of $3.0 million and mortgage notes of $6.7 million [8] - Presidio sold 51 model homes for approximately $24.8 million in 2024, recognizing a gain of approximately $3.4 million [10][29] - As of December 31, 2024, the company had approximately $12.3 million in net real estate assets, a decrease from approximately $144.2 million in 2023 [4] Impairments and Charges - A non-cash impairment charge of approximately $2.0 million was recognized in 2024, primarily related to goodwill and real estate assets [4][5] - The impairment on commercial properties was attributed to a loan maturity and inability to reach an agreement with lenders, leading to a decision to impair the property’s book value [4][5] Dividends - No distributions were declared for Series A Common Stock in 2024, while Series D Preferred Stock maintained a consistent distribution of $0.19531 per month [18][19]

Group 1: Company Overview - Conduit Pharmaceuticals has secured a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders such as Lupus and ANCA Vasculitis, positioning the company for clinical development and strategic partnerships [1][2] - The company is focused on developing Phase 2-ready assets and employs an integrated platform-driven approach powered by artificial intelligence (AI) and cybernetics, aiming for exit through third-party license deals following successful clinical trials [4] Group 2: Market Potential - The U.S. autoimmune disease market is projected to reach $150 billion by 2030, with Lupus affecting approximately 1.5 million Americans and ANCA Vasculitis impacting 200,000 patients annually, indicating a growing demand for innovative treatments [2] - Conduit's patent protection, which provides up to 20 years of exclusivity in the U.S., reinforces its competitive positioning and opens opportunities for commercial and strategic licensing partnerships [2][3] Group 3: Intellectual Property - Composition of matter patents are considered the gold standard in pharmaceutical intellectual property, offering strong market exclusivity and protection against generic competition [3] - The newly granted patent, along with existing approvals in Japan and Australia, positions Conduit favorably in three major pharmaceutical markets, with pending applications in Europe and other regions expected to expand its footprint [2]